U.S. opens Section 301 investigation into Germany’s pharmaceutical pricing policies

Friday, June 19, 2026Business & MarketsWell-covered3 frames

The U.S. has launched a trade investigation into Germany over its pharmaceutical pricing policies.
The investigation was opened under Section 301 of the Trade Act of 1974.
U.S. officials said the probe will examine whether Germany’s pricing or reimbursement of innovative medicines is unreasonable or discriminatory and burdens or restricts U.S. commerce.
U.S. officials have linked the probe to concerns that Germany underpays for innovative medicines, leaving American patients to bear a larger share of pharmaceutical research and development costs.
The investigation could lead to tariffs or other retaliatory U.S. trade measures against Germany.
The U.S. action comes as Germany is considering health-insurance or healthcare financing changes intended to reduce public spending, including on medicines.
U.S. Trade Representative Jamieson Greer said the administration is concerned by reports that Germany is fast-tracking legislation that would further reduce spending on innovative pharmaceuticals.
Germany has pushed back on the U.S. move, with Chancellor Friedrich Merz saying drug reimbursement and health-insurance policy are an internal German matter, while indicating Berlin would provide information to the U.S.

How left and right are reading this

Both agree: Germany’s drug-pricing rules are now being treated as a live trade dispute with possible retaliation, even as Berlin’s effort to curb healthcare spending and its claim of domestic authority remain central facts neither framing disputes.
They split on: Whether the story is about trade pressure intruding on Germany’s control over healthcare spending, or about forcing fairer burden-sharing when German drug pricing allegedly shifts more innovation costs onto American patients.

The U.S. has launched a trade investigation into Germany over its pharmaceutical pricing policies.
The investigation was opened under Section 301 of the Trade Act of 1974.
U.S. officials said the probe will examine whether Germany’s pricing or reimbursement of innovative medicines is unreasonable or discriminatory and burdens or restricts U.S. commerce.
U.S. officials have linked the probe to concerns that Germany underpays for innovative medicines, leaving American patients to bear a larger share of pharmaceutical research and development costs.
The investigation could lead to tariffs or other retaliatory U.S. trade measures against Germany.
The U.S. action comes as Germany is considering health-insurance or healthcare financing changes intended to reduce public spending, including on medicines.
U.S. Trade Representative Jamieson Greer said the administration is concerned by reports that Germany is fast-tracking legislation that would further reduce spending on innovative pharmaceuticals.
Germany has pushed back on the U.S. move, with Chancellor Friedrich Merz saying drug reimbursement and health-insurance policy are an internal German matter, while indicating Berlin would provide information to the U.S.

Facts first. Then every angle.